ACHV - Achieve Life Sciences, Inc.
| Previous Close | 3.4000 |
| Open | 3.3400 |
| Bid | 3.0900 x 800 |
| Ask | 3.5100 x 1000 |
| Day's Range | 3.3400 - 3.6825 |
| 52 Week Range | 1.0400 - 14.3100 |
| Volume | 123,417 |
| Avg. Volume | 1,742,451 |
| Market Cap | 23.524M |
| Beta (3Y Monthly) | 3.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1930 |
| Earnings Date | Jun 10, 2019 - Jun 14, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
CNW Group•6 days agoAchieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
- PR Newswire•15 days ago
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research•25 days ago
ACHV: Final Enrollee, Final Visit
Achieve Life Sciences, Inc. (ACHV) announced that its final enrollee had completed their final visit in the Phase IIb ORCA-1 trial on Wednesday. As a reminder the ORCA-1 (Ongoing Research of Cytisinicline for Addiction) trial is evaluating the effectiveness of cytisinicline for smoking cessation. The trial was designed as a multicenter, double blind, placebo-controlled trial in adult smokers randomized in a 2:2:1 ratio at 1.5 mg, 3.0 mg and placebo.
- PR Newswire•28 days ago
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications.
- PR Newswire•2 months ago
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
SEATTLE, Wash. and VANCOUVER, British Columbia , April 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development ...
- Benzinga•2 months ago
The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
- PR Newswire•2 months ago
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Data Safety Monitoring Committee (DSMC) met on March 28, 2019 to conduct its second and final safety review of the ORCA-1 Trial. The DSMC is an independent committee that advises on continuation or stopping of clinical trials based upon safety and study conduct considerations. The ORCA-1 DSMC has had the responsibility for safeguarding the interests of trial subjects by assessing the safety of the interventions and monitoring the conduct of the ORCA-1 trial.
- Zacks Small Cap Research•2 months ago
ACHV: Fiscal Year 2018 Operational and Financial Results
Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.
- ACCESSWIRE•2 months ago
What Do the Clinical Updates at Achieve Life Sciences Mean for Cytisinicline
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on Achieve Life Sciences, Inc. (ACHV), a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic. On March 14th, the company provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. 2018 was a remarkable year of executing on the development plan for cytisinicline as a treatment for nicotine addiction and as an aid to smoking cessation.
- PR Newswire•2 months ago
Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time.
- ACCESSWIRE•2 months ago
Four Healthcare Stocks Picking Up Speed On Friday
CORAL GABLES, FL / ACCESSWIRE / March 15, 2019 / The future successes of the healthcare stock market are intrinsically entwined with whether, or not, healthcare companies are aptly prepared to rise to ...
- PR Newswire•2 months ago
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia , March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- Zacks Small Cap Research•2 months ago
ACHV: A Reason to Quit is a Reason to Buy
Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.
- PR Newswire•3 months ago
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
SEATTLE and VANCOUVER, British Columbia , March 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...
- GlobeNewswire•3 months ago
Predictive Technology Group Names Jay M. Moyes to Its Board of Directors
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.
- ACCESSWIRE•3 months ago
Healthcare Stocks Leading the Sector
HENDERSON, NV / ACCESSWIRE / February 25, 2019 / The cost of healthcare has been outpacing inflation. According to Investor's Business Daily, the U.S. soon will ''spend nearly 20% of its gross domestic ...
- Simply Wall St.•3 months ago
Could The Achieve Life Sciences, Inc. (NASDAQ:ACHV) Ownership Structure Tell Us Something Useful?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Achieve Life Sciences, Inc. (NASDAQ:ACHV)Read More...
- ACCESSWIRE•3 months ago
Four Healthcare Stocks Looking to Close Out a Strong Week
Nearly every day, headlines are popping up surrounding these innovative companies in the healthcare industry as they tackle the prevalent need for qualitative care. Whereas other industries may have different core values and purposes, healthcare companies are tasked with keeping consumers healthy and amid that responsibility, if done correctly, lies the potential for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Zosano Pharma Corporation (ZSAN), Achieve Life Sciences Inc (ACHV), and Aurora Cannabis Inc (ACB) represent four healthcare companies focused on the advancement of the global healthcare industry.
- MarketWatch•3 months ago
Achieve Life Sciences' stock rockets on heavy volume after update results of smoking-cessation drug trial
Shares of Achieve Life Sciences Inc. rocketed 73% to pace all premarket gainers in active trade Friday, after the company reported upbeat results from a trial of its smoking-cessation drug. Trading volume reached 1.8 million shares ahead of the open, compared with the full-day average of about 151,000 shares. The company said it evaluated repeat doses of cytisinicline in 26 healthy volunteer smokers, who smoked an average 17.2 cigarettes a day. By the 26th day of treatment, there was an averag80% reduction in cigarettes smoked, 82% reduction in expired carbon monoxide and 46% had stopped smoking. Cytisinicline was well tolerated, with only "transient, mild-to-moderate headache" as the most common adverse event. "Given the short 25-day treatment period, the abstinence rates observed are impressive, particularly since subjects were not required to commit to quitting and received minimal behavioral support during the study," said Chief Medical Officer Cindy Jacobs. The stock has tumbled 87% over the past 12 months through Thursday, while the S&P 500 has gained 2.6%.
- PR Newswire•3 months ago
Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
SEATTLE and VANCOUVER, British Columbia, Feb. 22, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Study results will be presented today, Friday, February 22nd, at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting in San Francisco. The study evaluated the repeat-dose PK and PD effects of 1.5 mg and 3.0 mg cytisinicline in 26 healthy volunteer smokers when administered over the standard 25-day course of treatment.
- PR Newswire•3 months ago
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, Feb. 20, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period, with secondary analyses being conducted on smoking cessation rates, safety, and compliance.
- Zacks•5 months ago
5 Top Rising P/E Stocks to Enjoy Solid Gains
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- PR Newswire•5 months ago
Achieve Announces Update on Cytisinicline Clinical Development Program
SEATTLE and VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration (FDA) has confirmed that they are in agreement with Achieve's Initial Pediatric Study Plan, specifically, providing a full waiver for evaluating cytisinicline in a pediatric population. The reasons for the full waiver were based on the low numbers of children smoking under the age of 12 and the logistical difficulties of recruiting treatment-seeking smokers in the adolescent age group.
